The Global Preclinical Antibacterial Pipeline - Editors in Conversation

Explore the global preclinical antibacterial pipeline in this 38-minute conversation with Valeria Gigante, Team Lead at the World Health Organization's AMR Division. Delve into the process of reviewing the antibacterial pipeline, recognize progress and gaps in antibiotic discovery, and identify opportunities to overcome hurdles in early-stage antibacterial research and development. Gain insights on bacterial priority pathogen lists, research targeting, innovation challenges, pipeline composition, and future prospects. Understand the importance of antibiotic discovery in combating antimicrobial resistance and the economic challenges faced by the field. Learn about the latest WHO report on preclinical and clinical antibacterial development, methodologies used, and the composition of current pipelines, including IND-enabling phases and mechanism of action considerations.

Introduction
Bacterial Priority Pathogen List
Research and Targeting
CDC vs WHO
WHO fungal pathogen priority list
Methodology
Innovation
Innovation vs Inhibitors
Size of antibacterial research programs
High failure rate of antibacterial compounds
Lack of interest and investment
Pipeline composition
INDEnabling Phase
Mechanism of Action
Narrow Spectrum
Preclinic Programs
Limitations
Future